In a November 2017 study by Professor Claude Wischik, of Aberdeen University and executive chairman of TauRx Therapeutics said, “In addition to the reduction in brain atrophy, we were surprised to see the large cognitive effects of treatment in the patient group with the higher blood levels of hydromethylthionine at the 8 mg daily dose … the effect was around 7.5 points, or three times that seen from current routine Alzheimer's treatments, and would be equivalent to an 85% reduction in cognitive decline over 65 weeks."